Amanda Kesner-Hays

Amanda Kesner-Hays has a diverse work experience spanning over several years. Amanda began their career as a Graduate Student Fellow at the University of California in 1998. Amanda later worked as a Post-doctoral researcher at the university before joining Keryx Biopharmaceuticals in 2005. At Keryx Biopharmaceuticals, Amanda held various roles including Clinical Data Associate, Clinical Research Associate (Consultant), Drug Safety Associate, and Clinical Research Coordinator. In 2007, they joined Exelixis as a Drug Safety Associate, where they remained until 2011. During their time at Exelixis, Amanda also worked as a Drug Safety Scientist at Advanced Clinical from 2017 to 2018. Amanda then joined FibroGen, Inc. as a Senior Drug Safety Scientist from 2014 to 2016. In 2011, Amanda joined JANSSEN Alzheimer Immunotherapy as a Senior Drug Safety Associate, later being promoted to Scientist, Pharmacovigilance Operations. Amanda remained at JANSSEN Alzheimer Immunotherapy until 2014. From 2017 to 2019, Amanda also worked as a Clerk for the Citizens Bond Oversight Committee. Recently, in 2023, they joined Corcept Therapeutics as a Senior Director, Safety Science. Throughout their career, Amanda has gained experience in various aspects of drug safety, pharmacovigilance, risk management, and clinical research.

Amanda Kesner-Hays obtained a Bachelor of Science degree in Biology from the Massachusetts Institute of Technology from 1992 to 1996. Later, they pursued a Ph.D in Pharmacology from UCLA between 1998 and 2003. Furthermore, Amanda completed their education by earning a Master of Public Health degree in Public Health from The George Washington University- Milken Institute School of Public Health between 2016 and 2018.